GSK · NYSE, OTC · CIK 0001131399

GSK plc

GSK plc’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 26, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of GBP 32.7B and net income of GBP 6.3B, according to its XBRL data on EDGAR. Its EDGAR record lists 1 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
GBP 32.7B
Net income, FY2025
GBP 6.3B
Form 4 filings on record, past 12 months
1

Company overview

Legal name (as filed)
GSK plc
Tickers
GSK, GLAXF
SEC Central Index Key (CIK)
0001131399
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
LONDON
State or country of incorporation
United Kingdom
Fiscal year ends
—
SEC filer category
Large accelerated filer
Position in SEC ticker list
#163 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from GSK plc’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in GBP; the fiscal year is named for the calendar year in which it ends.

Revenue
GBP 24.7BFY2021GBP 29.3BFY2022GBP 30.3BFY2023GBP 31.4BFY2024GBP 32.7BFY2025
Net income
GBP 5.1BFY2021GBP 15.6BFY2022GBP 5.3BFY2023GBP 3.0BFY2024GBP 6.3BFY2025
GSK annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
RevenueGBP 24.7BGBP 29.3BGBP 30.3BGBP 31.4BGBP 32.7B
Net incomeGBP 5.1BGBP 15.6BGBP 5.3BGBP 3.0BGBP 6.3B
Diluted EPSGBP 1.08GBP 3.66GBP 1.20GBP 0.62GBP 1.39
Total assetsGBP 79.1BGBP 60.1BGBP 59.0BGBP 59.5BGBP 61.1B
Cash and equivalentsGBP 1.4BGBP 879.0MGBP 748.0MGBP 943.0MGBP 761.0M

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

GSK latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 6, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 26, 20266-KRIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA· period Oct 26, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about GSK plc, by form type:

6-K ×33424B2 ×2144 ×1S-8 ×1CERT ×18-A12B ×1FWP ×1
GSK recent filings
FiledFormWhat it isOriginal
Oct 26, 20266-KRIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA· period Oct 26, 2026Document · Index
Oct 26, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Oct 26, 2026Document · Index
Oct 26, 20266-KJEMPERLI DATA SHOW 76% COMPLETE RESPONSE RATE· period Oct 26, 2026Document · Index
Oct 26, 20266-KPOSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER· period Oct 26, 2026Document · Index
Oct 21, 20266-KUS FDA APPROVES HIBSAGO FOR CHRONIC HEPATITIS B· period Oct 21, 2026Document · Index
Oct 19, 20266-KJEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER· period Oct 19, 2026Document · Index
Oct 19, 20266-KRIS-REZ POSITIVE EARLY DATA IN LUNG CANCER· period Oct 19, 2026Document · Index
Oct 15, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Oct 15, 2026Document · Index
Oct 14, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Oct 14, 2026Document · Index
Oct 13, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Oct 13, 2026Document · Index
Oct 13, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Oct 13, 2026Document · Index
Oct 13, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Oct 8, 20266-KWENDY BECKER CBE - NEW DIRECTORSHIP· period Oct 8, 2026Document · Index
Oct 6, 20266-KADMISSION TO TRADING· period Oct 6, 2026Document · Index
Oct 1, 20266-KTOTAL VOTING RIGHTS· period Oct 1, 2026Document · Index
Sep 24, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Sep 24, 2026Document · Index
Sep 22, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Sep 22, 2026Document · Index
Sep 22, 2026CERTNYSE CERTIFICATIONDocument · Index
Sep 15, 20266-KGSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA· period Sep 15, 2026Document · Index
Sep 15, 20268-A12B8-A12BDocument · Index
Sep 15, 20266-KReport of a foreign private issuer· period Sep 15, 2026Document · Index
Sep 14, 20266-KRIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA· period Sep 14, 2026Document · Index
Sep 14, 20266-KJIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC· period Sep 14, 2026Document · Index
Sep 11, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Sep 11, 2026Document · Index
Sep 10, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Sep 10, 2026Document · Index
Sep 10, 20266-KJAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE· period Sep 10, 2026Document · Index
Sep 10, 2026424B2Prospectus (pricing supplement)Document · Index
Sep 9, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Sep 9, 2026Document · Index
Sep 9, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Sep 9, 2026Document · Index
Sep 9, 2026FWPFWPDocument · Index
Sep 8, 2026424B2Prospectus (pricing supplement)Document · Index
Sep 8, 20266-KReport of a foreign private issuer· period Sep 8, 2026Document · Index
Sep 1, 20266-KTOTAL VOTING RIGHTS· period Sep 1, 2026Document · Index
Sep 1, 20266-KMRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III· period Sep 1, 2026Document · Index
Aug 26, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Aug 26, 2026Document · Index
Aug 24, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Aug 24, 2026Document · Index
Aug 24, 20266-KFIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN· period Aug 24, 2026Document · Index
Aug 24, 20266-KUS FDA TO REVIEW JEMPERLI FOR RECTAL CANCER· period Aug 24, 2026Document · Index
Aug 20, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 18, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Aug 18, 2026Document · Index

Insider filing activity

1 Form 4 filings appear in GSK plc’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001131399 and XBRL company facts. GSK plc on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.